BMRN » Topics » Item 2.02 Results of Operations and Financial Condition.

This excerpt taken from the BMRN 8-K filed Jul 30, 2009.

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2009, BioMarin Pharmaceutical, Inc. (the “Company”) announced financial results for the second quarter ended June 30, 2009. The Company’s press release issued on July 30, 2009 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

In it’s press release, the Company included net income for the quarter and six months ended June 30, 2009, the quarter and six months ended June 30, 2008 and the year ended December 31, 2008 and an estimate of net income for the year ending December 31, 2009, each not determined in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). The non-GAAP net income for the second quarter of 2008 and 2009 excluded the non-cash stock compensation expense and certain nonrecurring material items. The non-GAAP net income for the six months ended June 30, 2009 and the six months ended June 30, 2008 excluded the non-cash stock compensation expense, certain nonrecurring material items and the tax effect of the adjustments. The anticipated non-GAAP net income for the year ending December 31, 2009 and actual results for the year ended December 31, 2008 excluded the non-cash stock compensation expense for 2008, management’s estimate of the non-cash stock compensation expense for 2009, certain other nonrecurring material items and the tax effect of the adjustments for 2008 and 2009. Reconciliations for such non-GAAP financial measures to the comparable GAAP financial measures are included in the press release attached hereto as Exhibit 99.1.

The Company believes that this non-GAAP information is useful to investors, taken in conjunction with the Company’s GAAP information because it provides additional information regarding the performance of the Company’s core ongoing business, Naglazyme, Kuvan and Aldurazyme and development of its pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the Company believes that the additional information enhances investors’ overall understanding of the Company’s business and prospects for the future. Further, the Company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.


This excerpt taken from the BMRN 8-K filed Nov 1, 2007.

Item 2.02. Results of Operations and Financial Condition.

On November 1, 2007, BioMarin Pharmaceutical Inc. (the “Company”) announced financial results for its third quarter and nine months ended September 30, 2007. The Company’s press release issued on November 1, 2007 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits.

 

  (a) Financial Statements of Business Acquired.

Not Applicable.

 

  (b) Pro Forma Financial Information.

Not Applicable.

 

  (c) Shell Company Transactions.

Not Applicable.

 

  (d) Exhibits.

Exhibit 99.1 Press Release of the Company dated November 1, 2007.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

BioMarin Pharmaceutical Inc., a Delaware corporation

    (Registrant)

Date November 1, 2007

 

/s/ G. Eric Davis

    G. Eric Davis
    Vice President, General Counsel

EXHIBIT INDEX

 

Exhibit No.  

Description

Exhibit 99.1   Press Release of the Registrant dated November 1, 2007

 

-2-

This excerpt taken from the BMRN 8-K filed Feb 20, 2007.

Item 2.02. Results of Operations and Financial Condition.

On February 20, 2007, BioMarin Pharmaceutical Inc. (the “Company”) announced financial results for its fourth quarter and year ended December 31, 2006. The Company’s press release issued on February 20, 2007 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01.

   Financial Statements and Exhibits.
(a)    Financial Statements of Business Acquired.
   Not Applicable.
(b)    Pro Forma Financial Information.
   Not Applicable.
(c)    Shell Company Transactions.
   Not Applicable.
(d)    Exhibits.
   Exhibit 99.1         Press Release of the Company dated February 20, 2007.

 

-2-


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

BioMarin Pharmaceutical Inc., a Delaware corporation

    (Registrant)
Date   February 20, 2007  

/s/ G. Eric Davis

   

G. Eric Davis

Vice President, General Counsel

 

-3-


EXHIBIT INDEX

 

Exhibit No.   

Description

Exhibit 99.1    Press Release of the Registrant dated February 20, 2007

 

-4-

This excerpt taken from the BMRN 8-K filed Nov 1, 2006.

Item 2.02. Results of Operations and Financial Condition.

On November 1, 2006, BioMarin Pharmaceutical Inc. (the “Company”) announced financial results for its third quarter ended September 30, 2006. The Company’s press release issued on November 1, 2006 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

This excerpt taken from the BMRN 8-K filed May 5, 2005.

Item 2.02 Results of Operations and Financial Condition.

 

On May 5, 2005, BioMarin Pharmaceutical Inc. (the “Company”) announced financial results for its first quarter ended March 31, 2005. The Company’s press release issued on May 5, 2005 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

This excerpt taken from the BMRN 8-K filed Feb 23, 2005.

Item 2.02. Results of Operations and Financial Condition.

 

On February 23, 2005, BioMarin Pharmaceutical Inc. (the “Company”) announced financial results for its fourth quarter and year ended December 31, 2004. The Company’s press release issued on February 23, 2005 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

This excerpt taken from the BMRN 8-K filed Jan 26, 2005.

Item 2.02 Results of Operations and Financial Condition.

 

On January 26, 2005, the Company issued a press release announcing certain preliminary, unaudited net sales results for the fourth quarter and the fiscal year ended December 31, 2004 for its Orapred® and Aldurazyme® products. The company also provided fiscal year 2005 sales guidance for both products.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki